Welcome to our dedicated page for Optimi Health news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Optimi Health Corp. reports on its role as a commercial-stage pharmaceutical manufacturer of regulated botanical wellness drug products, including GMP-manufactured MDMA capsules and natural botanical research compound capsules. Company updates commonly cover Health Canada-licensed production, export permits, finished dosage forms, and supply into regulated medical access pathways.
Recurring news themes include shipments and clinical use under Australia’s Authorised Prescriber Scheme, products supplied for PTSD and treatment-resistant depression, access through Canada’s Special Access Program, and initiatives to expand manufacturing capability to ibogaine. Optimi also reports capital-market actions, financing documents, investor presentations, and regulatory readiness tied to its cross-border commercial strategy.
Optimi Health (OTCQX: OPTHF) filed an offering document on April 23, 2026, in connection with a planned Nasdaq Capital Market listing and a previously announced listed issuer financing offering (the "Offering").
The Offering will include common shares, with price and terms to be set at market pricing; closing remains subject to approvals including the Canadian Securities Exchange, Nasdaq and SEC review.
Optimi Health (OTCQX: OPTHF) launched an Ibogaine Initiative on April 20, 2026 to extend its Health Canada‑licensed GMP psychedelic manufacturing platform to include ibogaine supply and support research.
The move follows a U.S. Executive Order directing federal agencies to accelerate psychedelic research, an FDA confirmation of IND clearance for ibogaine, and an ARPA‑H funding match beginning with $50 million.
Optimi Health (OTCQX: OPTHF) reported early clinical rollout of its naturally derived 5 mg psilocybin capsules for treatment-resistant depression (TRD) in Australia under the Authorised Prescriber Scheme on February 26, 2026. First patients of 2026 were treated after Optimi's initial 2026 psilocybin shipment.
Product was dispensed via Optimi's licensed Australian pharmacy partner under approved import permits, produced at Optimi's accredited Canadian facility and stated to comply with TGA quality guidelines. Treatment data are being captured in Australia's national registry.
Optimi Health (OTCQX: OPTHF) announced the export of GMP-manufactured 5 mg naturally derived psilocybin capsules to Australia for treatment-resistant depression under Australia’s Authorised Prescriber Scheme on February 19, 2026.
The shipment is Optimi's second finished drug in that scheme, complements prior 40 mg and 60 mg MDMA supplies, and is produced under a Health Canada Drug Establishment Licence. Treatment outcomes will be captured via Australia’s national patient registry in partnership with ANU.
Optimi Health (OTCQX: OPTHF) reported the first MDMA-assisted treatments of 2026 are underway at authorised clinics across Australia under the Authorised Prescriber Scheme. The company supplies 60 mg and 40 mg MDMA capsules under a Health Canada Drug Establishment Licence and cites no SAEs recorded under the Scheme as of September 16, 2025.
Patient-reported outcomes are being collected by Australian National University and the Australian Department of Veterans' Affairs announced a $740 million veterans rehabilitation plan that includes psychedelic-assisted therapy support.
Optimi Health (OTCQX: OPTHF) completed its first 2026 export of MDMA capsules to Australia under the Authorised Prescriber Scheme on February 9, 2026. The shipment comprised 1,000 MDMA capsules (60 mg), sufficient for over 300 authorised PTSD treatment sessions, following required Australian import and Health Canada export permits.
Patient-reported outcomes are being collected by the Australian National University to contribute to real-world evidence, and an Australian licensed pharmacy partner serves as importer of record and national distributor.
Optimi Health (OTCQX: OPTHF) completed its first 2026 production cycle, manufacturing 1,000 MDMA capsules (60 mg) and 1,000 naturally derived psilocybin capsules (5 mg) intended for supply into Australia under the Authorised Prescriber Scheme. Final packaging, labelling and batch release were completed under Optimi's Health Canada Drug Establishment Licence. The capsules are GMP-compliant and supported by Certificates of Analysis, and Australian import permits were issued to allow shipment into Australia's regulated healthcare system.
Optimi said the release positions the company to expand patient access for PTSD and treatment-resistant depression across Australia, and provided contact points for Australian and global enquiries.
Optimi Health (OTCQX: OPTHF) announced management will present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026. CEO Dane Stevens will host a virtual presentation on Wednesday, January 21, 2026 at 11:30 a.m. ET and will hold one-on-one virtual meetings with institutional investors during the event.
Registration is mandatory; a live audio webcast and archived replay will be available via the registered webcast link. Media and investors may contact MZ Group at OPTHF@mzgroup.us to schedule meetings or email investors@optimihealth.ca for investor inquiries.
Optimi Health (OTCQX: OPTHF) announced the immediate appointment of Jason Mosberian to its board of directors, effective December 18, 2025. Mr. Mosberian is a Sauder School of Business graduate and CPA (2011) with six years in public practice audit and over a decade at BFL Canada as Senior Vice President and Partner, focusing on risk management and insurance across manufacturing, distribution and life sciences.
He replaces Jonathan Schintler on the board. The appointment is subject to approval by the Canadian Securities Exchange. The company thanked Mr. Schintler for his contributions.
Optimi Health (OTCQX: OPTHF) announced it supplied GMP 40mg and 60mg MDMA capsules for MAPS Israel's Healing October 7th clinical trial for trauma-related PTSD. The multicenter, open-label non-inferiority study will compare group vs individual MDMA-assisted therapy and plans to enroll 168 participants, with initial Israeli Ministry of Health approval granted for the first 20 patients.
The trial is sponsored by Sheba Medical Center and runs at Lev Hasharon and Be'er Sheva mental health centres; Optimi completed its first export of MDMA capsules to Israel to support the program.